GSK's vaccine has just hit the mark in a phase ... all awarded by the European Patent Office and covering recombinant RSV antigens and compositions and methods for making them.

In trials, GSK’s vaccine significantly reduced ... identified a protein in RSV a decade ago that looked like a promising antigen for vaccine development. Both Arexvy and Abrysvo target this ...

and the clinical effectiveness of palivizumab and motavizumab validate RSV F protein as an attractive vaccine antigen. These epidemiological and clinical data combined with recent advances in RSV ...

The FDA will review a new prefilled syringe presentation of Shingrix (zoster vaccine recombinant, adjuvanted).

The global vaccines market was valued at $ ... 18 to 59 years of age at risk of developing severe respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD). In October 2024, ...

Among adults aged 75 and older, RSV was linked to a substantial burden of hospitalizations, ICU admissions, and in-hospital deaths before vaccines were available.

This review seeks to familiarize the readers with RSV rapid antigen-detection tests, describe their performance characteristics and comment on their strengths and weaknesses. The authors will ...

The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning about the risk of developing Guillain-Barré syndrome (GBS), a rare ...

Jan 7 (Reuters) - GSK (GSK.L), opens new tab and Pfizer's (PFE.N), opens new tab respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing a rare ...

U.S. sales of RSV vaccines have declined after regulators narrowed the age group eligible for the shots and determined they would be a one-time vaccination for now. For Pfizer and GSK, RSV ...

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for ...

GSK and Pfizer's respiratory syncytial virus (RSV) vaccines will carry warnings that they can increase the risk of developing a rare neurological disorder, the U.S. Food Drug Administration said on ...